Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8792638 | 1.00 | CHRM2 (0.32) | CHRM2CHRM1CHRM3SLC6A3SLC6A2 | |
| SCHEMBL2486522 | 1.00 | CHRM2 (0.32) | CHRM2CHRM1CHRM3SLC6A3SLC6A2 | |
| SCHEMBL4966930 | 0.91 | SLC6A3 (0.38) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL990458 | 0.91 | SLC6A3 (0.38) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL8792121 | 0.91 | SLC6A3 (0.38) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| Pyridine SCHEMBL8555633 | 0.87 | SLC6A3 (0.33) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL28736377 | 0.83 | — | — | |
| SCHEMBL3905650 | 0.77 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL412203 | 0.76 | CPN1 (0.36) | CHRM2CHRM1CHRM3SLC6A3SLC6A2 | |
| SCHEMBL589885 | 0.76 | CHRM2 (0.35) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176250-B1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS CH (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-09-30 | — | — | US | disclosed |
| EP-2176250-A1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009010299-A1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | MC4R, MC5R, MC3R | CHRM2 358/4885CHRM1 352/4885CHRM3 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.